Anna Porwit

List of Publications by Year
in descending order

43 papers	1,069 citations	623734 14 h-index	414414 32 g-index
44 all docs	44 docs citations	44 times ranked	1415 citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre‑analytical and technical issues—Recommendations from the European ‹scp›LeukemiaNet‹/scp›. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European ‹scp›LeukemiaNet‹/scp› International ‹scp›MDS‑Flow‹/scp› Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
3	Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic ‹scp›Flow‑Self‹/scp› Organizing Maps algorithm. Cytometry Part B - Clinical Cytometry, 2022, 102, 134-142.	1.5	5
4	A series of case studies illustrating the role of flow cytometry in the diagnostic work‑up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	5
5	Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?. Current Oncology Reports, 2022, 24, 1015-1022.	4.0	8
6	EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 621-646.	2.8	2
7	Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry. Cytometry Part B - Clinical Cytometry, 2021, 100, 409-420.	1.5	14
8	Infiltration of CD163‑, PD‑L1‑ and FoxP3‑positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. British Journal of Haematology, 2021, 193, 520-531.	2.5	12
9	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. European Journal of Haematology, 2021, 107, 275-282.	2.2	8
10	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. Leukemia and Lymphoma, 2021, 62, 2637-2647.	1.3	2
11	Unsupervised flow cytometry analysis in hematological malignancies: A new paradigm. International Journal of Laboratory Hematology, 2021, 43, 54-64.	1.3	13
12	The Plasmacytoid Dendritic Cell CD123+ Compartment in Acute Leukemia with or without RUNX1 Mutation: High Inter-Patient Variability Disclosed by Immunophenotypic Unsupervised Analysis and Clustering. Hemato, 2021, 2, 572-585.	0.6	2
13	Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome. Annals of Hematology, 2021, 100, 1711-1722.	1.8	5
14	Definition of Erythroid Differentiation Subsets in Normal Human Bone Marrow Using FlowSOM Unsupervised Cluster Analysis of Flow Cytometry Data. HemaSphere, 2021, 5, e512.	2.7	7
15	p53 is associated with high‑risk and pinpoints ‹i›TP53‹/i› missense mutations in mantle cell lymphoma. British Journal of Haematology, 2020, 191, 796-805.	2.5	31
16	Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2020, 98, 399-411.	1.5	24
17	Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification. Journal of Hematopathology, 2020, 13, 79-88.	0.4	6
18	Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 183-194.	1.5	33

#	Article	IF	Citations
19	Advances in Bone Marrow Diagnostics of Patients with Cytopenia. Pathobiology, 2019, 86, 5-6.	3.8	1
20	Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting. Blood, 2019, 134, 2755-2755.	1.4	0
21	Proteomic Profiling of Diffuse Large B-Cell Lymphomas. Pathobiology, 2018, 85, 211-219.	3.8	6
22	Characteristics of Lymphoproliferative Disorders with More Than One Aberrant Cell Population as Detected by 10â€Color Flow Cytometry. Cytometry Part B - Clinical Cytometry, 2018, 94, 230-238.	1.5	12
23	Visualization of Cell Composition and Maturation in the Bone Marrow Using 10â€Color Flow Cytometry and Radar Plots. Cytometry Part B - Clinical Cytometry, 2018, 94, 219-229.	1.5	25
24	Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis. Blood, 2018, 132, 4437-4437.	1.4	0
25	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	3.5	74
26	The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. Blood Advances, 2017, 1, 2392-2398.	5.2	15
27	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10â€Color flow cytometry diagnosis and HyperCVAD therapy. American Journal of Hematology, 2016, 91, 283-286.	4.1	40
28	Fulminant anaplastic large cell lymphoma (ALCL) concomitant with primary cytomegalovirus (CMV) infection, and human herpes virus 8 (HHV-8) infection together with Epstein-Barr-virus (EBV) reactivation in a patient with asymptomatic HIV-infection. Infectious Agents and Cancer, 2016, 11, 46.	2.6	3
29	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. Haematologica, 2016, 101, e145-e148.	3.5	26
30	The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. Blood, 2016, 128, 3246-3246.	1.4	0
31	Screening bone marrow samples for abnormal lymphoid populations and myelodysplasiaâ€related features with one 10â€color 14â€antibody screening tube. Cytometry Part B - Clinical Cytometry, 2015, 88, 253-260.	1.5	31
32	Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?. Current Hematologic Malignancy Reports, 2015, 10, 309-317.	2.3	9
33	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 715-727.	0.4	7
34	Acute Leukemias of Ambiguous Origin. American Journal of Clinical Pathology, 2015, 144, 361-376.	0.7	46
35	Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014. Blood, 2015, 126, 4865-4865.	1.4	1
36	Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care. Blood, 2015, 126, 3848-3848.	1.4	1

#	Article	IF	Citations
37	Relapse of acute myeloid leukemia manifested by cholecystitis: A case report and review of the literature. International Journal of Surgery Case Reports, 2014, 5, 302-305.	0.6	6
38	ETV6 /FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia. Journal of Hematopathology, 2014, 7, 71-77.	0.4	13
39	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica, 2014, 99, 1041-1049.	3.5	116
40	Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?. Blood, 2013, 122, 1946-1946.	1.4	13
41	Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica, 2012, 97, 1209-1217.	3.5	136
42	Role of flow cytometry in diagnostics of myelodysplastic syndromesâ€"beyond the WHO 2008 classification. Seminars in Diagnostic Pathology, 2011, 28, 273-282.	1.5	20
43	Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood, 2011, 117, 3163-3171.	1.4	252